Zunhai Zhou

Central South University - Second Xiangya Hospital

Changsha, Hunan 410083

China

SCHOLARLY PAPERS

1

DOWNLOADS

78

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

Number of pages: 100 Posted: 21 Aug 2019
Peking University - Department of Endocrinology and Metabolism, Southern Medical University - Chenzhou No.1 People's Hospital, Tangshan Gongren Hospital, Xuzhou Medical University, Harrison International Peace Hospital, Qingdao University - Affiliated Hospital, China Three Gorges University (CTGU) - College of Medical Science, Jilin University (JLU) - Second Hospital, Jiangsu Province Hospital, China Meitan General Hospital, Chongqing University, Chongqing Medical University - Department of Endocrinology, Hebei Medical University, Tianjin Medical University - General Hospital, Government of the People's Republic of China - 306th Hospital, Baogang Hospital of Inner Mongolia, Cangzhou Central Hospital, Fudan University - Zhongshan Hospital, Sichuan University, Government of the People's Republic of China - Air Force Medical University, Shanghai Jiao Tong University (SJTU) - Xinhua Hospital, Central South University - Key Laboratory of Diabetes Immunology, Peking University, Central South University - Second Xiangya Hospital, Xiamen University - First Affiliated Hospital, Wuhan University - Zhongnan Hospital, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd and Shanghai Jiao Tong University (SJTU) - Department of Endocrinology and Metabolism
Downloads 78 (677,086)

Abstract:

Loading...